Astria Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Selling, General & Admin	25.7	19.24	14.81	11.85	8.77	Upgrade
Research & Development	42.13	34.26	15.55	25.59	18.32	Upgrade
Other Operating Expenses	15.2	0	164.62	0	0	Upgrade
Operating Expenses	83.03	53.5	194.98	37.44	27.09	Upgrade
Operating Income	-83.03	-53.5	-194.98	-37.44	-27.09	Upgrade
Other Expense / Income	-10.14	-1.67	-0.06	-0.14	-0.8	Upgrade
Pretax Income	-72.89	-51.83	-194.91	-37.3	-26.29	Upgrade
Net Income	-72.89	-51.83	-194.91	-37.3	-26.29	Upgrade
Preferred Dividends	0	0	24.44	0	0	Upgrade
Net Income Common	-72.89	-51.83	-219.35	-37.3	-26.29	Upgrade
Shares Outstanding (Basic)	30	15	9	3	2	Upgrade
Shares Outstanding (Diluted)	30	15	9	3	2	Upgrade
Shares Change	106.03%	63.81%	191.81%	63.87%	121.55%	Upgrade
EPS (Basic)	-2.42	-3.55	-24.58	-12.20	-14.10	Upgrade
EPS (Diluted)	-2.42	-3.55	-24.58	-12.20	-14.10	Upgrade
Free Cash Flow	-68.47	-43.62	-30.17	-32.52	-26.58	Upgrade
Free Cash Flow Per Share	-2.27	-2.98	-3.38	-10.63	-14.24	Upgrade
EBITDA	-72.89	-51.83	-194.91	-37.3	-26.29	Upgrade
EBIT	-72.89	-51.83	-194.91	-37.3	-26.29	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).